Cargando…

O8.8. NEUROCOGNITION IN ULTRA-HIGHRISK INDIVIDUALS AND RELATIONSHIP TO TRANSITION TO PSYCHOSIS, DEPRESSIVE DISORDER, AND FUNCTIONING: FINDINGS FROM THE NEURAPRO TRIAL

BACKGROUND: Neurocognitive impairments are a core feature of psychosis and major depressive disorder (MDD) and are associated with poorer functioning outcomes in these illnesses. Individuals at ultra-high risk (UHR) for psychosis have been shown to experience mild but significant cognitive impairmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Allott, Kelly, McGorry, Patrick, Bolt, Luke, Nelson, Barnaby, Markulev, Connie, Yuen, Hok Pan, Schaefer, Miriam, Mossaheb, Nilufar, Schlögelhofer, Monika, Smesny, Stephan, Hickie, Ian, Berger, Gregor, Chen, Eric, de Haan, Lieuwe, Nieman, Dorien, Nordentoft, Merete, Riecher-Rössler, Anita, Verma, Swapna, Thompson, Andrew, Yung, Alison, Paul Amminger, G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888569/ http://dx.doi.org/10.1093/schbul/sby015.244

Ejemplares similares

T49. THE NEURAPRO STUDY: ADHERENCE TO STUDY MEDICATION
por: Schlögelhofer, Monika, et al.
Publicado: (2018)

T9. CROSS-SECTIONAL ASSOCIATION OF MEMBRANE FATTY ACID COMPOSITION AND PSYCHOPATHOLOGY IN THE NEURAPRO-E STUDY
por: Berger, Maximus, et al.
Publicado: (2018)

T34. THE IMPACT OF ANTIDEPRESSANT USE ON THE TRANSITION TO PSYCHOSIS RATE IN THE NEURAPRO TRIAL
por: Schlögelhofer, Monika, et al.
Publicado: (2020)

Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial
por: Berger, Maximus, et al.
Publicado: (2019)

F25. NEURAPRO REVISITED: INCREASES IN LONG-CHAIN OMEGA-3 FATTY ACIDS IMPROVE FUNCTIONAL AND SYMPTOMATIC OUTCOMES IN ULTRAHIGH RISK PATIENTS
por: Paul Amminger, G, et al.
Publicado: (2018)

Corrigendum: Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial
por: Berger, Maximus, et al.
Publicado: (2020)

Effects of omega-3 polyunsaturated fatty acid supplementation on cognitive functioning in youth at ultra-high risk for psychosis: secondary analysis of the NEURAPRO randomised controlled trial
por: Cheng, Nicholas, et al.
Publicado: (2022)

S136. A NOVEL APPROACH FOR DEVELOPING PREDICTION MODEL OF TRANSITION TO PSYCHOSIS: DYNAMIC PREDICTION USING JOINT MODELLING
por: Yuen, Hok Pan, et al.
Publicado: (2018)

NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders—medium-term follow-up and clinical course
por: Nelson, B., et al.
Publicado: (2018)

Characterization and prediction of clinical pathways of vulnerability to psychosis through graph signal processing
por: Sandini, Corrado, et al.
Publicado: (2021)

Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis
por: Susai, Subash Raj, et al.
Publicado: (2022)

S8. RELATIONSHIP BETWEEN ALLOSTATIC LOAD AND POOR FUNCTIONAL CAPACITY IN YOUTH AT ULTRA-HIGH RISK FOR PSYCHOSIS
por: Berger, Maximus, et al.
Publicado: (2018)

Erythrocyte glutathione levels as long-term predictor of transition to psychosis
por: Lavoie, S, et al.
Publicado: (2017)

O10.8. A PLURIPOTENTIAL AT RISK MENTAL STATE: INITIAL RESULTS
por: Hartmann, Jessica A, et al.
Publicado: (2018)

Recent Meta-Analyses in the Clinical High Risk for Psychosis Population: Clinical Interpretation of Findings and Suggestions for Future Research
por: Nelson, Barnaby, et al.
Publicado: (2018)

Omega-6 to omega-3 polyunsaturated fatty acid ratio and subsequent mood disorders in young people with at-risk mental states: a 7-year longitudinal study
por: Berger, M E, et al.
Publicado: (2017)

Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study
por: Amminger, G. Paul, et al.
Publicado: (2015)

Commentary: Preventive Treatments for Psychosis: Umbrella Review (Just the Evidence)
por: Nelson, Barnaby, et al.
Publicado: (2020)

Niacin Skin Sensitivity Is Increased in Adolescents at Ultra-High Risk for Psychosis
por: Berger, Gregor E., et al.
Publicado: (2016)

Differential expression of the inflammation marker IL12p40 in the at-risk mental state for psychosis: a predictor of transition to psychotic disorder?
por: Föcking, Melanie, et al.
Publicado: (2016)

Obsessive-Compulsive Symptoms and Other Symptoms of the At-risk Mental State for Psychosis: A Network Perspective
por: Ong, Hui Lin, et al.
Publicado: (2021)

Impact of adverse childhood experiences on educational achievements in young people at clinical high risk of developing psychosis
por: Tognin, Stefania, et al.
Publicado: (2023)

Relationship between Erythrocyte Fatty Acid Composition and Psychopathology in the Vienna Omega-3 Study
por: Kim, Sung-Wan, et al.
Publicado: (2016)

T44. A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE EFFECTS OF VITAMIN B12, B6 AND FOLIC ACID ON COGNITION AND SYMPTOMS IN FIRST-EPISODE PSYCHOSIS: THE VITAMINS IN PSYCHOSIS STUDY
por: Allott, Kelly, et al.
Publicado: (2018)

Using clinical information to make individualized prognostic predictions in people at ultra high risk for psychosis
por: Mechelli, Andrea, et al.
Publicado: (2017)

Prediction of transition from ultra-high risk to first-episode psychosis using a probabilistic model combining history, clinical assessment and fatty-acid biomarkers
por: Clark, S R, et al.
Publicado: (2016)

Delayed sleep onset in depressed young people
por: Glozier, Nicholas, et al.
Publicado: (2014)

Impact of Comorbid Affective Disorders on Longitudinal Clinical Outcomes in Individuals at Ultra-high Risk for Psychosis
por: Schirmbeck, Frederike, et al.
Publicado: (2021)

Psychotic-Like Experiences: A Challenge in Definition and Assessment
por: Hinterbuchinger, Barbara, et al.
Publicado: (2021)

T21. DEVELOPMENT OF PROTEOMIC PREDICTION MODELS FOR OUTCOMES IN THE CLINICAL HIGH RISK STATE AND PSYCHOTIC EXPERIENCES IN ADOLESCENCE: MACHINE LEARNING ANALYSES IN TWO NESTED CASE-CONTROL STUDIES
por: Mongan, David, et al.
Publicado: (2020)

Role of aripiprazole in treatment-resistant schizophrenia
por: Mossaheb, Nilufar, et al.
Publicado: (2012)

White matter integrity in individuals at ultra-high risk for psychosis: a systematic review and discussion of the role of polyunsaturated fatty acids
por: Vijayakumar, Nandita, et al.
Publicado: (2016)

The Impact of Sex Differences on Odor Identification and Facial Affect Recognition in Patients with Schizophrenia Spectrum Disorders
por: Mossaheb, Nilufar, et al.
Publicado: (2018)

Evaluation of a Dutch school-based depression prevention program for youths in highrisk neighborhoods: study protocol of a two-armed randomized controlled trial
por: Kindt, Karlijn CM, et al.
Publicado: (2012)

Agreement between Self- and PhysicianSampling for Detection of HighRisk Human Papillomavirus Infections in Women Attending Cervical Screening at National Cancer Institute, Thailand
por: Sangrajrang, Suleeporn, et al.
Publicado: (2023)

T30. TIPPING POINTS – PREDICTING TRANSITIONS TO PSYCHOSIS IN AT-RISK YOUNG PEOPLE
por: Hartmann, Jessica A, et al.
Publicado: (2018)

Development of Proteomic Prediction Models for Transition to Psychotic Disorder in the Clinical High-Risk State and Psychotic Experiences in Adolescence
por: Mongan, David, et al.
Publicado: (2021)

M21. THE STEP TRIAL: A SEQUENTIAL MULTIPLE ASSIGNMENT RANDOMISED TRIAL (SMART) OF INTERVENTIONS FOR PATIENTS AT ULTRA-HIGH RISK OF PSYCHOSIS - STUDY RATIONALE, DESIGN AND BASELINE DATA
por: Nelson, Barnaby, et al.
Publicado: (2020)

T119. CAN SOME YOUNG PEOPLE RECOVER FROM FIRST-EPISODE PSYCHOSIS WITH INTEGRATED PSYCHOSOCIAL TREATMENT WITHOUT ANTIPSYCHOTIC MEDICATIONS? AN RCT TO ASSESS RISKS, BENEFITS, AND RANGE OF OUTCOMES
por: McGorry, Patrick, et al.
Publicado: (2018)

PM396. Associations of obsessive–compulsive symptoms with clinical and neurocognitive features in schizophrenia according to stage of illness
por: Kim, Sung-Wan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mfo1fa8a5f4ii0ftf98ha5r1pk